MEDICARE COVERAGE SIGNIFICANTLY EXPANDED FOR THE EVERSENSE E3 CGM SYSTEM

Written by Emily J. Thompson, Senior Investment Analyst

SENS-2.66%

Source: PRnewswire

Updated: Feb 12 2024

0mins

Source: PRnewswire

SENS

$7.31+Infinity%1D

Analyst Views on SENS

Wall Street analysts forecast SENS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SENS is 18.70 USD with a low forecast of 9.00 USD and a high forecast of 31.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Analyst Rating

4 Buy

1 Hold

0 Sell

Strong Buy

Current: 7.510

Low

9.00

Averages

18.70

High

31.00

Current: 7.510

Low

9.00

Averages

18.70

High

31.00

Mizuho

Outperform

NULL

downgrade

$40 -> $20

2025-11-10

Reason

Mizuho

Price Target

$40 -> $20

AI Analysis

2025-11-10

downgrade

Outperform

NULL

Reason

Mizuho lowered the firm's price target on Senseonics to $20 from $40 and keeps an Outperform rating on the shares post the Q3 report. The firm believes the company's setup remains favorable into Q4 amid tailwinds from the start of E365 new starts, renewals and expanding inserter network.

H.C. Wainwright

Buy

maintain

2025-11-06

Reason

H.C. Wainwright

Price Target

2025-11-06

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Senseonics to $18.50 from $1.40 and keeps a Buy rating on the shares. The firm cites the 1-for-20 reverse stock split for the target change.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for SENS

Unlock Now

TD Cowen

Buy

downgrade

$25 -> $15

2025-11-05

Reason

TD Cowen

Price Target

$25 -> $15

2025-11-05

downgrade

Buy

Reason

TD Cowen lowered the firm's price target on Senseonics to $15 from $25 and keeps a Buy rating on the shares. The firm updated its model following the recent stock split where their new target applies a sales multiple of 6.75 to our 2028 sales estimate and uses a 12% discount rate to account for commercial execution risk.

Barclays

NULL -> Overweight

maintain

$31

2025-11-05

Reason

Barclays

Price Target

$31

2025-11-05

maintain

NULL -> Overweight

Reason

Barclays adjusted the firm's price target on Senseonics to $31 from $1.50 and keeps an Overweight rating on the shares. The firm cites the the preliminary Q3 results and the recent reverse stock split for the target change.

About SENS

Senseonics Holdings, Inc. is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the diabetes community. Its glucose monitoring (CGM) systems Eversense 365 and Eversense E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. Its CGM systems are indicated for continually measuring glucose levels for up to 365 days for Eversense 365 and 180 days for Eversense E3 in persons with diabetes age 18 and older. Eversense consists of three primary components: a small sensor inserted subcutaneously under the skin by a healthcare provider; an external removable smart transmitter that receives, assesses and relays data from the sensor and provides vibratory alerts; and a mobile app that receives data from the transmitter and provides real-time glucose readings, alerts and other data the person's mobile device.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.